Literature DB >> 16870211

Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy.

Sinead M O'Brien1, Paul Scully, Peter Fitzgerald, Lucinda V Scott, Timothy G Dinan.   

Abstract

OBJECTIVE: Approximately 30% of patients with depression fail to respond to a selective serotonin reuptake inhibitor (SSRI). Few studies have attempted to define these patients from a biological perspective. Studies suggest that overall patients with depression show increased production of proinflammatory cytokines. We examined pro- and anti-inflammatory cytokine levels in patients who were SSRI resistant.
METHODS: Plasma concentrations of IL-6, IL-8, IL-10, TNF-alpha and sIL-6R were measured with enzyme linked immunosorbent assays (ELISA) in DSM-1V major depressives who were SSRI resistant, in formerly SSRI resistant patients currently euthymic and in healthy controls.
RESULTS: Patients with SSRI-resistant depression had significantly higher production of the pro-inflammatory cytokines IL-6 (p=0.01) and TNF-alpha (p=0.004) compared to normal controls. Euthymic patients who were formerly SSRI resistant had proinflammatory cytokine levels which were similar to the healthy subject group. Anti-inflammatory cytokine levels did not differ across the 3 groups.
CONCLUSION: Suppression of proinflammatory cytokines does not occur in depressed patients who fail to respond to SSRIs and is necessary for clinical recovery.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16870211     DOI: 10.1016/j.jpsychires.2006.05.013

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  126 in total

1.  Illness comorbidity as a biomarker?

Authors:  Hymie Anisman; Shawn Hayley
Journal:  J Psychiatry Neurosci       Date:  2012-07       Impact factor: 6.186

Review 2.  Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment?

Authors:  David Baumeister; Simone Ciufolini; Valeria Mondelli
Journal:  Psychopharmacology (Berl)       Date:  2015-08-14       Impact factor: 4.530

Review 3.  Inflammation: depression fans the flames and feasts on the heat.

Authors:  Janice K Kiecolt-Glaser; Heather M Derry; Christopher P Fagundes
Journal:  Am J Psychiatry       Date:  2015-09-11       Impact factor: 18.112

Review 4.  New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors.

Authors:  Michael Maes; Zdenĕk Fišar; Miguel Medina; Giovanni Scapagnini; Gabriel Nowak; Michael Berk
Journal:  Inflammopharmacology       Date:  2012-01-24       Impact factor: 4.473

Review 5.  Glial abnormalities in substance use disorders and depression: does shared glutamatergic dysfunction contribute to comorbidity?

Authors:  Mark J Niciu; Ioline D Henter; Gerard Sanacora; Carlos A Zarate
Journal:  World J Biol Psychiatry       Date:  2013-09-12       Impact factor: 4.132

6.  Systemic Inhibition of Soluble Tumor Necrosis Factor with XPro1595 Exacerbates a Post-Spinal Cord Injury Depressive Phenotype in Female Rats.

Authors:  Kaitlin Farrell; John D Houle
Journal:  J Neurotrauma       Date:  2019-07-10       Impact factor: 5.269

Review 7.  Neuroinflammation and comorbidity of pain and depression.

Authors:  A K Walker; A Kavelaars; C J Heijnen; R Dantzer
Journal:  Pharmacol Rev       Date:  2013-12-11       Impact factor: 25.468

Review 8.  A critical review of human endotoxin administration as an experimental paradigm of depression.

Authors:  Nicole DellaGioia; Jonas Hannestad
Journal:  Neurosci Biobehav Rev       Date:  2009-08-08       Impact factor: 8.989

Review 9.  The impact of vascular burden on late-life depression.

Authors:  Micaela Santos; Enikö Kövari; Patrick R Hof; Gabriel Gold; Constantin Bouras; Panteleimon Giannakopoulos
Journal:  Brain Res Rev       Date:  2009-09-08

Review 10.  Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies.

Authors:  Jennifer M Loftis; Marilyn Huckans; Benjamin J Morasco
Journal:  Neurobiol Dis       Date:  2009-11-26       Impact factor: 5.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.